Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19214802 | 1.00 | DPP4 (0.36) | DPP4DPP8DPP9SLC6A3OPRD1 | |
| SCHEMBL8739022 | 0.85 | DPP4 (0.36) | DPP4DPP8DPP9SLC6A3OPRD1 | |
| SCHEMBL4551356 | 0.85 | DPP4 (0.36) | DPP4DPP8DPP9SLC6A3OPRD1 | |
| SCHEMBL27769588 | 0.82 | CTSK (0.39) | DPP4DPP8DPP9SLC6A3OPRD1 | |
| SCHEMBL19901776 | 0.81 | AAK1 (0.36) | DPP4DPP8DPP9SLC6A3OPRD1 | |
| SCHEMBL20279044 | 0.81 | DPP4 (0.39) | DPP4DPP8DPP9SLC6A3OPRD1 | |
| SCHEMBL7964213 | 0.81 | DPP4 (0.39) | DPP4DPP8DPP9SLC6A3OPRD1 | |
| SCHEMBL7964218 | 0.81 | DPP4 (0.39) | DPP4DPP8DPP9SLC6A3OPRD1 | |
| SCHEMBL2627123 | 0.80 | DPP4 (0.34) | DPP4DPP8DPP9SLC6A3OPRD1 | |
| SCHEMBL13342875 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635556-B1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARM INC (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3176154-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20160318852-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9469654-B2 | Bicyclic oxa-lactam kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9359375-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150297595-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2015-10-22 | — | — | US | disclosed |
| US-20150252056-A1 | BICYCLIC OXA-LACTAM KINASE INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2015-09-10 | — | — | US | disclosed |
| US-9040530-B2 | 1,2,4-triazine-6-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8952027-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150038492-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8846928-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140113931-A1 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-8063058-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS INC. (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2009136995-A2 | INHIBITORS OF SYK PROTEIN KINASE | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297595-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | DPP4 3510/4885DPP8 3806/4885DPP9 2706/4885 |
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | DPP4 2218/4885DPP8 2634/4885DPP9 2121/4885 |
| US-20150252056-A1 | BICYCLIC OXA-LACTAM KINASE INHIBITORS | SYK, BTK, JAK2 | DPP4 2552/4885DPP8 1916/4885DPP9 1700/4885 |
| US-20140113931-A1 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | SYK, LCK, BTK | DPP4 2338/4885DPP8 978/4885DPP9 1377/4885 |
| US-20160318852-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | DPP4 2218/4885DPP8 2634/4885DPP9 2121/4885 |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | SYK, BTK, JAK1 | DPP4 3510/4885DPP8 3806/4885DPP9 2706/4885 |
| US-20150038492-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | DPP4 2218/4885DPP8 2634/4885DPP9 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.